Clinical trial
Phase II Trial of Velcade (Bortezomib) in Patients With Previously Untreated Multiple Myeloma
NCT00153920 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Trial of Velcade (Bortezomib) in Patients With Previously Untreated Multiple Myeloma
- Lead sponsor
- Dana-Farber Cancer Institute
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2003
- Completion date
- September 30, 2008
- Enrollment
- 66 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.